Xenon Gas Inhalation for Neuroinflammation
This study is testing the safety of xenon gas inhalation in healthy volunteers aged 55 to 75. Researchers want to see if xenon gas could eventually help people with neurodegenerative diseases like Alzheimer's. You would inhale xenon gas mixed with oxygen for different lengths of time (10, 20, 30, or 45 minutes). The main goal is to track any side effects you might have during and after treatment. This is an early-stage study, and xenon gas is not yet approved by the FDA, meaning it's only available through research studies like this one. There are 16 participants planned for this study.
- Study design
- This is an open-label study, meaning both you and the researchers will know which treatment group you are in. It involves 16 healthy participants, divided into four groups based on the duration of xenon gas inhalation.
- What's involved
- You would have a screening period of up to 7 days to check your eligibility. After treatment, you would have follow-up visits on days 1, 3, and 7. The maximum study duration for each person is 15 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety monitoring until 7 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Exploratory Clinical Study to Assess Safety and Efficacy of Xenon Gas Inhalation to Control Neuroinflammation
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ilya Ilin, PhD · PRINCIPAL_INVESTIGATOR · General Biophysics
- Howard L Weiner, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women"s Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants with Xenon Treatment-Related Adverse Events at Each Treatment Duration as Assessed by CTCAE v4.0From treatment to the end of follow up at 7 days
To determine the safety of xenon gas inhalation for 10, 20, 30, and 45 minutes in healthy volunteers. Investigators anticipate to observe no sedation, no nausea, and no vomiting. Measured Parameters for Safety Assessments during Xenon Administration (Intraoperative - every five (5) minutes): * Heart rate * Blood pressure * Respiratory rate * Body temperature * Peripheral blood oxygenation * Changes in capnometry * Electrocardiographic parameters and printed rhythm strip * Adverse events Depth of sedation will be assessed and recorded every five (5) minutes during Xenon Gas administration and upon completion of procedure and recovery, utilizing the Modified Observer's Assessment of Alertness/Sedation Scale (MOAA/S) by the anesthesiologist. Adverse events of special interest for this inhaled anesthetic: vomiting, hemodynamic changes requiring drug intervention, and sedation unresponsive to verbal commands. AEs will be assessed during repeated visits on day 1, day 3, and day 7.